Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Atara Biotherap (ATRA)

Atara Biotherap (ATRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 836,633
  • Shares Outstanding, K 54,151
  • Annual Sales, $ 0 K
  • Annual Income, $ -230,700 K
  • 60-Month Beta 2.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.29
  • Number of Estimates 5
  • High Estimate -1.27
  • Low Estimate -1.32
  • Prior Year -1.75
  • Growth Rate Est. (year over year) +26.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.87 +20.05%
on 11/14/19
16.40 -5.79%
on 12/12/19
+2.35 (+17.89%)
since 11/13/19
3-Month
10.38 +48.84%
on 10/31/19
16.40 -5.79%
on 12/12/19
+0.29 (+1.91%)
since 09/13/19
52-Week
10.38 +48.84%
on 10/31/19
43.36 -64.37%
on 12/14/18
-27.16 (-63.74%)
since 12/13/18

Most Recent Stories

More News
Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel(R) Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting

61 patients with diverse EBV-associated diseases, including 26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel (tabelecleucel) EAP study

ATRA : 15.45 (-3.38%)
Look for Shares of Atara Biotherape to Potentially Pullback after Yesterday's 4.27% Rise

Atara Biotherape (NASDAQ:ATRA) traded in a range yesterday that spanned from a low of $13.84 to a high of $14.48. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high...

ATRA : 15.45 (-3.38%)
Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced...

ATRA : 15.45 (-3.38%)
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why

Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ATRA : 15.45 (-3.38%)
Coherus Bioscien has the Best Relative Performance in the Biotechnology Industry (CHRS , VNDA , ATRA , EPZM , RDUS )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

ATRA : 15.45 (-3.38%)
CHRS : 18.52 (+1.48%)
VNDA : 16.73 (-1.47%)
Atara Biotherapeutics: 3Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Atara Biotherapeutics Inc. (ATRA) on Thursday reported a loss of $71.9 million in its third quarter.

ATRA : 15.45 (-3.38%)
Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported...

ATRA : 15.45 (-3.38%)
Atara Biotherapeutics to Present Tab-cel(R) Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced...

ATRA : 15.45 (-3.38%)
Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced...

ATRA : 15.45 (-3.38%)
Atara Biotherapeutics Announces Executive Departures

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced...

ATRA : 15.45 (-3.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ATRA with:

Business Summary

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta...

See More

Key Turning Points

2nd Resistance Point 16.56
1st Resistance Point 16.01
Last Price 15.45
1st Support Level 15.10
2nd Support Level 14.75

See More

52-Week High 43.36
Fibonacci 61.8% 30.76
Fibonacci 50% 26.87
Fibonacci 38.2% 22.98
Last Price 15.45
52-Week Low 10.38

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar